Intended Use
The Human SDMA (Symmetric Dimethylarginine) ELISA Kit is intended for the quantitative determination of SDMA (Symmetric Dimethylarginine) in human serum or plasma. The Human SDMA (Symmetric Dimethylarginine) ELISA Kit is for research use only and not to be used in clinical, therapeutic or diagnostic procedures.
Storage
On arrival, store the kit at 2-8 °C. Once opened the kit is stable until its expiry date.
For stability of prepared reagents refer to Preparation of Reagents.
Do not use components beyond the expiration date shown on the labels.
Do not mix various lots of any kit component within an individual assay.
General Description
Dosing of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function an essential component of diagnostics in clinical medicine. Furthermore, even modest impairment of renal function has been recognized as a cardiovascular risk factor. As the most commonly used marker of renal excretory function, serum creatinine concentration, does not adequately respond to mild to moderate impairment of renal function, more sensitive markers for renal excretory function are urgently seeked, especially in mild stages of renal impairment. SDMA is a methylated derivative of the amino acid L-arginine (symmetric dimethylarginine). SDMA is eliminated from the body exclusively by renal excretion; therefore SDMA plasma concentration is tightly related to renal function. Thus, quantification of plasma SDMA is an adequate means to assess renal function, as could be demonstrated in a series of recent clinical trials: In 18 clinical studies involving more than 2,100 patients systemic SDMA concentrations were highly correlated with inulin clearance as well as with various clearance estimates and better corresponded to mild renal function impairment than serum creatinine.
Thus, SDMA exhibits properties of a reliable marker of renal function. Furthermore, there is evidence showing that elevated SDMA levels, as they may occur in renal function impairment, may prospectively indicate future risk of cardiovascular disease and mortality independently of the level of renal impairment.
COA
Publication 
Loading ......
